TRACON Pharmaceuticals Stock News

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) major shareholder Opaleye Management Inc. acquired 21,964 shares of the companys stock in a transaction on Wednesday, December 15th. The shares were purchased at an average cost of $2.43 per share, with a total value of $53,372.52. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which []

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) major shareholder Opaleye Management Inc. acquired 15,204 shares of the companys stock in a transaction on Monday, December 13th. The stock was acquired at an average cost of $2.64 per share, for a total transaction of $40,138.56. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, []

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) major shareholder Opaleye Management Inc. purchased 22,733 shares of TRACON Pharmaceuticals stock in a transaction that occurred on Monday, December 6th. The shares were bought at an average price of $2.26 per share, for a total transaction of $51,376.58. The transaction was disclosed in a document filed with the SEC, which []

State Street Corp purchased a new stake in TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 72,954 shares of the biopharmaceutical companys stock, valued at approximately $473,000. State Street Corp owned about 0.38% of TRACON Pharmaceuticals as of its most []

Northern Trust Corp acquired a new stake in TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 17,337 shares of the biopharmaceutical companys stock, valued at approximately $113,000. Northern Trust Corp owned about 0.11% of TRACON Pharmaceuticals []

New York, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies:

Shares of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) have received a consensus rating of Buy from the six analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1 year price target among []

TRACON Pharmaceuticals (NASDAQ:TCON) Inc reported that its partners had announced that envafolimab (KN035) had received marketing authorization from the Chinese National Medical Products Administratio

TRACON Pharmaceuticals (NASDAQ:TCON) Inc reported that its partners had announced that envafolimab (KN035) had received marketing authorization from the Chinese National Medical Products Administratio

TRACON Pharmaceuticals (NASDAQ:TCON) Inc reported that its partners had announced that envafolimab (KN035) had received marketing authorization from the Chinese National Medical Products Administratio

Adagio Therapeutics (NASDAQ:ADGI) and TRACON Pharmaceuticals (NASDAQ:TCON) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations. Insider and Institutional Ownership 39.8% of Adagio Therapeutics shares are owned by institutional investors. Comparatively, 46.3% [] The post Adagio Therapeutics (NASDAQ:ADGI) vs. TRACON Pharmaceuticals (NASDAQ:TCON) Head-To-Head Analysis appeared first on ETF Daily News .

Wall Street brokerages predict that TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) will report earnings per share (EPS) of ($0.35) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for TRACON Pharmaceuticals earnings, with the lowest EPS estimate coming in at ($0.40) and the highest estimate coming in at ($0.30). TRACON Pharmaceuticals posted []

TRACON Pharmaceuticals (NASDAQ:TCON) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations. Analyst Ratings This is a breakdown of recent recommendations and price targets for TRACON Pharmaceuticals []

Insider sales are generally a sign the market is about to drop, but not everyone's selling. Here are five companies with insider buying.